Control of tachykinin-evoked acetylcholine release from rat striatal slices by dopaminergic neurons.
The regulation of tachykinin-evoked acetylcholine release by the dopaminergic system in the neostriatum was examined. We studied the effect of selective and potent tachykinin agonists for each subtype of receptor ([Sar9,Met(O2)11]-Substance P for NK1; [Nle10]-Neurokinin A4-10 for NK2; and senktide for NK3) on endogenous acetylcholine release from rat striatal slices where the dopaminergic system was modified either by 6-hydroxydopamine lesion or by dopamine receptor antagonists. Unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway induced a decrease in senktide-evoked acetylcholine release and an increase in the effect of [Nle10]-Neurokinin A4-10. The same results were obtained after chronic haloperidol treatment, whereas SCH-23390 or clozapine treatment had no effect on tachykinin-evoked acetylcholine release, suggesting an involvement of D2 receptors. 6-hydroxydopamine lesion induced a diminution in the density of NK3 receptor, which could be related to the reduction in senktide-evoked acetylcholine release.
Alberch
J
J
Departament de Biologia Cellular i Anatomia Patològica, Hospital de Bellvitge, Facultat de Medicina, Universitat de Barcelona, Spain.
Arenas
E
E
Pérez-Navarro
E
E
Marsal
J
J
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D017072:Neostriatum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018042:Receptors, Neurokinin-3 / Q000187:drug effects / Q000378:metabolism; D013373:Substance P / Q000031:analogs & derivatives / Q000378:metabolism; D015320:Tachykinins / Q000494:pharmacology*
D001552:Benzazepines; D015259:Dopamine Agents; D010446:Peptide Fragments; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; C054724:senktide; D013373:Substance P; D016627:Oxidopamine; D003024:Clozapine; D006220:Haloperidol; D000109:Acetylcholine; D004298:Dopamine